Although causality cannot be inferred from FAERS data and the results should be interpreted cautiously, we identified some signals of disproportionate reporting of DASSI for certain GnRH-a therapies. These hypothesis-generating findings may raise clinical awareness and inform a risk-informed monitoring framework (e.g., baseline assessment of mood and suicidality, patient/caregiver education on warning signs, and early follow-up), but require confirmation in well-designed epidemiologic studies.
Liu et al. (Mon,) studied this question.